Browsing by Author Thi, EP

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中
Showing results 7 to 13 of 13 < previous 
TitleAuthor(s)Issue DateViews
 
Long-term suppression maintained after cessation of AB-729 treatment and comparable on-treatment response observed in HBeAg+ subjects. Poster Presentation (SAT443)
Proceeding/Conference:The International Liver Congress 2022, 22-26 June 2022. Journal of Hepatology
Yuen, RMFBerliba, ESukeepaisarnjaroen, WHolmes, JLeerapun, ATangkijvanich, PStrasser, SJucov, AGane, EJThi, EPSevinsky, NMedvedeva, ESharma, VGray, KAntoniello, DPicchio, GSims, KEley, T
2022
 
Reduction of hepatitis B surface antigen mediated by RNA interference therapeutic AB-729 in chronic hepatitis B patients is associated with T cell activation and a decline in exhausted CD8 T cells. Poster Presentation (SAT397)
Proceeding/Conference:The International Liver Congress 2022, 22-26 June 2022. Journal of Hepatology
Ganchua, SCParatala, BIott, CGane, EJYuen, RMFEley, TSims, KGray, KAntoniello, DLam, AMSofia, MJPicchio, GThi, EP
2022
1
 
Repeat dosing of the GalNAc-siRNA AB-729 in subjects with chronic hepatitis B results in robust and sustained HBsAg suppression
Proceeding/Conference:Journal of Hepatology
Yuen, RMFBerliba, ESukeepaisarnjaroen, WStrasser, STangkijvanich, PHolmes, JLeerapun, AJucov, AThi, EPWattamwar, TSofia, MJSevinsky, HGray, KAntoniello, DEley, TPicchio, GSims, KGane, E
2021
14
 
Safety and pharmacodynamics of the GALNAC-siRNA AB-729 in subjects with chronic hepatitis B infection
Proceeding/Conference:Hepatology
Yuen, RMFBerliba, EKim, YJHolmes, JALim, YSStrasser, SISchwabe, CJucov, ALee, ACHThi, EPHarasym, TPamulapati, GRWattamwar, PKunta, JSofia, MJSevinsky, HGray, KEley, TPicchio, GRSims, KGane, EJ
2020
19
 
Safety, pharmacokinetics, and antiviral activity of the capsid inhibitor AB-506 from Phase 1 studies in healthy subjects and those with hepatitis B
Journal:Hepatology Communications
Yuen, MFBerliba, ESukeepaisarnjaroen, WAhn, SHTanwandee, TLim, YSKim, YJPoovorawan, KTangkijvanich, PSchwabe, CEley, TBrown, JLee, ACHThi, EPParatala, BMani, NSofia, MJPicchio, GSims, KDGane, EJ
4-Oct-2022
 
Safety, tolerability, pharmacokinetics (PK), and antiviral activity of the 3rd generation capsid inhibitor AB-836 in healthy subjects(HS) and subjects with chronic hepatitis B (CHB). Poster Presentation (SAT392)
Proceeding/Conference:The International Liver Congress 2022, 22-26 June 2022. Journal of Hepatology
Gane, EJJucov, AKolomiichuk, LEley, TBrown, JKing, YMedvedeva, EChernyakhovskyy, MMani, NCole, AGKultgen, SGPamulapati, RThi, EPHarasym, TODugyala, RChaudhari, SSofia, MJChild, MPicchio, GSims, KYuen, RMF
2022
 
Safety, tolerability, pharmacokinetics (PK), and antiviral activity of the capsid inhibitor (CI) AB-506 in healthy subjects (HS) and chronic hepatitis B (CHB) subjects
Proceeding/Conference:Hepatology
Yuen, RMFBerliba, ESukeepaisarnjaroen, WAhn, SHTanwandee, TLim, Y-SKim, YJPoovorawan, KTangkijvanich, PChan, HLYEley, TBrown, JMoore, CLee, ACHKim, JThi, EPMani, NRijnbrand, RCole, ASofia, MJPicchio, GRSims, KGane, EJ
2019
48
Showing results 7 to 13 of 13 < previous